Sphenopalatine ganglion block in primary headaches

John G. Burkett, Matthew S. Robbins, Carrie E. Robertson, Mihriye Mete, Nicolas P. Saikali, Rashmi B. Halker Singh, Jessica Ailani
2019 Neurology Clinical Practice  
The sphenopalatine ganglion (SPG), in the pterygopalatine fossa, is a known current and historical target for therapeutic intervention in headache disorders because of its role in cranial autonomics and vasodilation. There remains an overall lack of well-established SPG treatment protocols, particularly with the advent of newer commercial devices. A 22 multiple-choice question survey was created to evaluate clinical practice patterns with SPG block and sent to members of the American Headache
more » ... ciety (AHS). Questions focused on determining indications, preferred applicators, medications applied, perceived efficacy, tolerability, and reimbursement. One hundred seventy-two of 1,346 (12.8%) AHS members participated. Ninety-three respondents (56.3%) had performed SPG blocks on 50 or fewer patients. The SphenoCath (42.4%) and the Tx360 (41.8%) were the most common methods of application. Ease of use was the top reason for provider preference in applicator type. SPG blocks were mostly used as an as-needed one-time procedure. When a scheduled protocol was used, twice weekly for 6 weeks was most common. Chronic migraine was the most commonly treated headache disorder and rated the most likely to respond to SPG block. Experienced clinicians found SPG more helpful as a stand-alone treatment and tended to report that acute relief was not predictive of enduring response. The variety of responses strongly suggests that clinicians would benefit from formalized protocols for SPG blocks. More experienced clinicians may have developed individualized protocols that they feel are more effective. The lack of evidence-based protocols contribute to clinicians not performing SPG blocks more frequently.
doi:10.1212/cpj.0000000000000773 pmid:33520413 pmcid:PMC7837428 fatcat:qwhohhvmmjhsxg5526hkhflvsy